DORVAL, QC, May 8, 2014 /CNW/ - Novartis Pharmaceuticals Canada Inc. is
pleased to announce that Timothy Maloney has been appointed Country
Head and President, effective April 1, 2014. Mr. Maloney brings with
him 28 years of pharmaceutical industry experience in both primary care
and specialty product markets.
Since joining Novartis in 2003, he has held various positions of
increasing responsibility in the United States and Global commercial
organizations. After leading the U.S. cardiovascular business, he moved
to Switzerland to lead the $7-billion Global Cardiovascular and
Metabolism franchise. In 2011, Mr. Maloney successfully launched the
company's Primary Care Franchise, contributing to the success of
treatments for diabetes and hypertension, as well as building a
world-class portfolio of products for respiratory diseases.
Mr. Maloney will also immediately start contributing to the overall
Canadian research-based pharmaceutical industry by his appointment to
the Board of Directors of Rx&D, Canada's Research-Based Pharmaceutical
Prior to joining Novartis, Mr. Maloney held sales and marketing
leadership positions with Pfizer and its predecessor companies, Upjohn
and Pharmacia. He holds a Bachelor of Science (BSc) in biology from the
State University of New York (SUNY) at Plattsburgh, NY. He and his
family will be relocating to Montreal from Basel, Switzerland.
About Novartis Pharmaceuticals Canada Inc.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field,
is committed to the discovery, development and marketing of innovative
products to improve the well-being of all Canadians. In 2012, the
company invested close to $100 million in research and development in
Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600
people in Canada. For further information, please consult www.novartis.ca.
Novartis Pharmaceuticals Canada Inc. is a subsidiary of Novartis AG
which provides innovative healthcare solutions that address the
evolving needs of patients and societies. Headquartered in Basel,
Switzerland, Novartis Group of Companies offers a diversified portfolio
to best meet these needs: innovative medicines, eye care, cost-saving
generic pharmaceuticals, preventive vaccines, over-the-counter and
animal health products. Novartis is the only global company with
leading positions in these areas. In 2013, the Group achieved net sales
of USD 57.9 billion, while R&D throughout the Group amounted to
approximately USD 9.9 billion (USD 9.6 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately
135,000 full-time-equivalent associates and sell products in more than
150 countries around the world. For more information, please visit http://www.novartis.com.
Image with caption: "Timothy Maloney, Country Head and President, Novartis Pharmaceuticals Canada Inc. (CNW Group/Novartis Pharmaceuticals Canada Inc.)". Image available at: http://photos.newswire.ca/images/download/20140508_C6673_PHOTO_EN_39973.jpg
SOURCE: Novartis Pharmaceuticals Canada Inc.
For further information:
Novartis Media Relations
Novartis Pharmaceuticals Canada Inc.
+1 514 633-7873